New funding from CEPI will help take a promising nanoparticle vaccine platform into early clinical development, with the aim of speeding up how we respond to future outbreaks. More ⬇️

🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic. More in the press release ⬇️

CEPI's latest newsletter is now available! From funding to accelerate clinical develop of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV). Eligibility and how to apply: cepi.my.site.com/call-for-pro...

CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV). Eligibility and how to apply: cepi.my.site.com/call-for-pro...

CEPI's latest newsletter is now available! From funding to accelerate clinical develop of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

CEPI's latest newsletter is now available! From funding to accelerate clinical development of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic. More in the press release ⬇️

The next pandemic could begin anywhere, at any moment. And the risk of a deadly outbreak is only rising. But it doesn’t have to be that way. CEPI 3.0 is our plan to move the world from reactive response to proactive protection.

The @ec.europa.eu announced €73.7m in #HorizonEurope support to @cepi.net for 2026–2027. Part of the #EU’s new Global Health Resilience Initiative, this funding will support vaccine R&D and help strengthen #preparedness when new health threats emerge👇 #WHA79 @florikafinkhooijer.bsky.social

Europe is reinforcing its commitment to a world protected from epidemic and pandemic threats as current outbreaks underscore the persistent risk posed by infectious diseases. Today at #WHA79, the @ec.europa.eu announced €73.7 million commitment to CEPI for 2026 and 2027. 🇪🇺 More: bit.ly/4dxBcdE

Singapore is strengthening global defences against future epidemic and pandemic threats. Today at #WHA79, Singapore pledged US$12 million to support our CEPI 3.0 strategy—a powerful signal of leadership from a global innovation hub. 🇸🇬 More: bit.ly/4dxBcdE

At #WHA79 in Geneva, we were honoured to welcome major new financial commitments from the European Union (€73.7 million) and Singapore (US$12 million) to support our work to transform the world’s ability to prevent and respond to epidemic and pandemic threats.

LIVE: watch our official #WHA79 side event entitled: “From Outbreak Response to System Readiness: Building the Global and Regional Capabilities to Stop Pandemic Threats in 100 Days” Click the link to watch in real time 📺 bit.ly/4eReCPm

📣Call for Proposals now open. @cepi.net + PATH seek technical partners for the Biospecimen Sourcing Initiative to enable rapid collection of and access to survivor samples for faster outbreak response. Please share this opportunity across your networks. 🔗Apply: https://bit.ly/4nLHBGV

The hantavirus outbreak has raised familiar questions: what if this were something more transmissible, something with pandemic potential? Speaking to BBC Inside Science, CEPI’s Dr Nicole Lurie explored exactly that scenario, outlining how the world could respond if faced with a new “Disease X”.

Dr Nicole Lurie: we must be "poised and ready." The #hantavirus outbreak is a reminder that preparedness must begin before a crisis. CEPI is already supporting early vaccine building blocks needed to give the world a head start if the threat escalates ⬇️

Thank you to @cepi.net for highlighting our efforts to help prevent the next major coronavirus outbreak. Made-in-Canada science has a critical role to play in protecting the health of people, animals and communities around the world. cepi.net/inside-vidos... @usask.ca

We sat down with CEPI’s Director of R&D programmes, Dr Mandeep Singh Dhingra, MD, for the first instalment of our new CEPI 3.0 explainer series to learn more about the viral family approach and its role in the CEPI 3.0 Strategy: cepi.net/cepi-30-expl...

The outbreak of #Hantavirus on board a cruise ship carrying passengers from more than 20 countries is worrying, although the World Health Organization currently rates the risk to the global population as low.

Discover the latest advances in pandemic preparedness in the April edition of CEPI Updates & Insights 📰 This month takes a look at the first-of-its-kind Phase III H5N1 vaccine trial, our new partnerships, CEPI 3.0 campaign updates and plenty more.

#WorldImmunisationWeek 🧵 From protecting children against once-devastating diseases like smallpox to enabling rapid responses to emerging infectious threats like COVID-19, vaccines have saved millions of lives and remain one of the most powerful tools in global health. (1/7)

Last week, the CEPI team joined health leaders at the 27th Assembly of ECOWAS Health Ministers in Freetown, Sierra Leone, to share progress in the fight against Lassa fever and CEPI’s plans to make the 100 Days Mission a reality. sciencenigeria.com/lassa-vaccin...

"We’re using science and creativity to make sure that vaccines not only exist, but that they are also equitably distributed." A new @thelancet.com profile explores Dr Amadou Sall’s extensive career across epidemic response and vaccine equity.

Last week, @cepi.net and PAHO announced an expanded collaboration to strengthen regulatory systems and pharmacovigilance programs across Latin America and the Caribbean, supporting rapid, equitable access to vaccines, including during pandemics. www.ghtcoalition.org/blog/researc...

H5N1 bird flu is spreading across species. A new rapid response mRNA vaccine developed by Moderna could be a game‑changer for global pandemic preparedness. Meet Clare, one of the first volunteers in the CEPI-funded clinical trial, as she gets her first dose.

CEPI and Pasteur Network have signed a Memorandum of Understanding to expand collaboration on epidemic and pandemic preparedness, vaccine research, manufacturing and innovation. More ⬇️

Our #100DaysMission aims to accelerate vaccine development timelines to 100 days. Had this been achieved for COVID-19, around eight million lives might have been saved. Discover the 100 Days Mission: https://cepi.net/100-days-mission

The CEPI 3.0 Investment Case calls for US$2.5 billion in new funding to unlock the plan’s transformational epidemic and pandemic-busting potential and secure a safer, better prepared future for all. Read the details ⬇️ #SecureTheFuture https://bit.ly/4cqqNjc

For an interview with France's L'Express, CEPI’s Deputy CEO, Aurélia Nguyen, reflects on the growing role of artificial intelligence in epidemic and pandemic preparedness, including the potential biosecurity risks. More: https://bit.ly/4cldTmv

Could the key to stopping future pandemics be… right under our noses? 👃🦠 Imperial is leading @musiccproject.bsky.social, a global project exploring #vaccines that could block infection at the point of entry. Read more in this @cepi.net blog 👇 cepi.net/could-our-no...

CEPI and Pan American Health Organization are expanding their exisiting partnership to help strengthen regulatory systems and pharmacovigilance across Latin America and the Caribbean, supporting more agile approvals and improved vaccine safety monitoring. More: cepi.net/cepi-and-pah...

"The 100 Days Mission reflects our shared commitment to deliver faster, safer and more effective preparedness and response for all countries." A powerful message of support for CEPI 3.0 and the 100 Days Mission from Indonesia's Minister of Health, Budi Sadikin ⬇️

CEPI CEO Richard Hatchett sets out why pandemic preparedness remains a global priority. From the growing threat of emerging diseases, including the potential misuse of AI, to declining investment in public health, the risks are evolving. At the same time, the tools to respond are improving. More ⬇️

Our March newsletter has just landed 🗞️ This month zooms in on how regulatory preparedness will be a crucial enabler of the 100 Days Mission. It also features all the regular updates, including CEPI 3.0 campaign progress, our latest R&D partnerships and plenty more.

Late last year, CEPI, @path.org and Africa CDC convened 80+ experts from 20 countries in Nairobi to move RPECA from concept to a concrete roadmap that establishes a regionally owned ecosystem for rapid clinical trials and real-world evidence generation. Discover the key takeaways: bit.ly/4rVQopT

📣Positive topline results from a CEPI-supported study of Bavarian Nordic's Mpox vaccine in 2-to-11-year-olds have been submitted to the European Medicines Agency, paving the way for the jab to be approved for use in younger age groups: www.bavarian-nordic.com/investor/new...

A new Springer Nature perspective featuring @Pfizer leaders explores how to make the 100 Days Mission a reality. Read the full article: link.springer.com/article/10.1...

Strengthening capabilities needed to advance a Lassa fever vaccine are also the same capabilities needed to ensure any vaccine can be developed, whether that’s for a known disease like Lassa fever or a future Disease X. This approach sits at the heart of CEPI 3.0 and the 100 Days Mission. More ⬇

The 100 Days Mission is the benchmark for pandemic preparedness, but achieving it requires more than scientific breakthroughs. It requires a shift from individual vaccines to building the broad capabilities needed for rapid response. More in our new blog ⬇️

The University of Oxford and Serum Institute of India have signed an IP licensing agreement to advance development and manufacturing of the CEPI-funded ChAdOx1 NipahB vaccine candidate - an important step toward strengthening global preparedness against Nipah virus.

CEPI strengthens global biosecurity with eight new partnerships ⬇️ The partnerships will help advance our biosecurity work. Selected through a competitive Request for Proposals, these organisations are global leaders in training, policy, laboratory infrastructure, and biorisk management.

"The 100 Days Mission is a game-changer" - H.E Dr Jean Kaseya, Director General, Africa CDC. In this supportive statement from Africa CDC, Dr Kaseya explains how CEPI's 100 Days Mission is helping the continent to #SecureTheFuture against the threat of epidemics and pandemics.

"In less than 10 years, CEPI has helped to redefine how the world develops vaccines for emerging infectious diseases, shifting from reactive crisis response to collaborative preparedness." - Dr Tedros Adhanom Ghebreyesus. A powerful endorsement of CEPI 3.0 from our @who.int partners.

Our February newsletter is live! It spotlights the launch of CEPI 3.0 Investment Case and Strategy. Inside, you’ll find a deep dive into our next strategic phase, messages of support, a dedicated reading corner and more.

A great video from our partners on the impact that CEPI's funding is having on clinical trial preparedness in the West Africa region ⬇️

Epidemics & pandemics are a defining #HealthSecurity challenge of our time. @cepi.net#HealthSecurityis working to transform the way we tackle today’s viral threats and get ahead of tomorrow’s. CEPI's 3.0 strategy aims to secure a safer, better prepared future for all: https://bit.ly/4cFE2y9 #SecureTheFuture

The Biospecimen Sourcing Initiative aims to facilitate the timely and ethical collection of biological samples during an outbreak: https://bit.ly/4qILZWZ Biospecimens from survivors are necessary for the rapid development of new vaccines, treatments & diagnostics. #100DaysMission @cepi.net

A new All Africa feature highlights both the progress made against Ebola — and the work still ahead — drawing on insights from CEPI CEO Richard Hatchett.

In mid-2025, CEPI welcomed its second cohort of Global South Fellows. Now, halfway through the year-long fellowship, we caught up with Dr Umar Ahmad—one of the Fellows embedded in CEPI’s Laboratory Research and Innovations department—to discuss his experience. Read the Q&A blog to learn more ⬇️